MX2021007843A - Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso. - Google Patents

Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.

Info

Publication number
MX2021007843A
MX2021007843A MX2021007843A MX2021007843A MX2021007843A MX 2021007843 A MX2021007843 A MX 2021007843A MX 2021007843 A MX2021007843 A MX 2021007843A MX 2021007843 A MX2021007843 A MX 2021007843A MX 2021007843 A MX2021007843 A MX 2021007843A
Authority
MX
Mexico
Prior art keywords
polypeptides
diseases
complement activation
modified
methods
Prior art date
Application number
MX2021007843A
Other languages
English (en)
Inventor
Christopher Thanos
Edwin L Madison
Eric Steven Furfine
Vanessa Soros
Mikhail Popkov
Kimberly Tipton
Matthew John Traylor
Jeffrey Charles Way
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2021007843A publication Critical patent/MX2021007843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21031—Urokinase (3.4.21.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)

Abstract

Se proporcionan polipéptidos de u-PA y proteínas de fusión que contienen los polipéptidos de u-PA. Los polipéptidos de u-PA se modifican para tener actividad y/o especificidad alterada de tal forma que escinden una proteína de complemento, tal como proteína de complemento C3, para inhibir de este modo la activación del complemento. Los polipéptidos de u-PA modificados y proteínas de fusión que inhiben la activación del complemento se pueden usar para tratamiento de enfermedades y condiciones que están mediadas por activación del complemento, o en las cuales la activación del complemento desempeña un papel. Estos trastornos incluyen trastornos isquémicos y de reperfusión, incluido infarto de miocardio y derrame cerebral, sepsis, enfermedades autoinmunitarias, retinopatías diabéticas, degeneración macular relacionada con la edad, rechazo de órganos trasplantados, enfermedades inflamatorias y enfermedades con un componente inflamatorio.
MX2021007843A 2018-12-28 2019-12-27 Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso. MX2021007843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862786302P 2018-12-28 2018-12-28
PCT/US2019/068839 WO2020140101A1 (en) 2018-12-28 2019-12-27 Modified urokinase-type plasminogen activator polypeptides and methods of use

Publications (1)

Publication Number Publication Date
MX2021007843A true MX2021007843A (es) 2021-08-11

Family

ID=69400631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007843A MX2021007843A (es) 2018-12-28 2019-12-27 Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.

Country Status (16)

Country Link
US (1) US20230242895A1 (es)
EP (1) EP3902913A1 (es)
JP (1) JP2022516725A (es)
KR (1) KR20210110848A (es)
CN (1) CN113661239A (es)
AU (1) AU2019413431A1 (es)
BR (1) BR112021012601A2 (es)
CA (2) CA3176021A1 (es)
CL (1) CL2021001710A1 (es)
CO (1) CO2021008338A2 (es)
IL (1) IL284323A (es)
JO (1) JOP20210146A1 (es)
MX (1) MX2021007843A (es)
PE (1) PE20211664A1 (es)
SG (1) SG11202106244RA (es)
WO (1) WO2020140101A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
CN114854728B (zh) * 2022-05-12 2023-11-24 云南师范大学 一种脯氨酸消旋酶及其制备和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569A (en) 1838-01-09 Caruiag-e-spiiln g
US5795A (en) 1848-09-19 Saddletree for carts
US237A (en) 1837-06-15 Egbert beale
US844A (en) 1838-07-17 Boiler for
US5324A (en) 1847-10-09 Cooking-stove
US5990A (en) 1848-12-26 of baltimore
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4997766A (en) 1986-07-11 1991-03-05 American Home Products Corporation Poly-kringle plasminogen activator
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0266032A1 (en) * 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5580559A (en) 1986-12-05 1996-12-03 Ciba-Geigy Corporation Hybrid plasminogen activator
NL8701021A (nl) 1987-04-29 1988-11-16 Stichting Centraal Lab Humane t-pa(u-pa) substitutie-mutant eiwitten, daarvoor coderend recombinant dna, getransfecteerde gastheercellen, bereiding van de mutant eiwitten, en farmaceutische preparaten.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
EP0336508A1 (en) * 1988-04-06 1989-10-11 K.U. Leuven Research & Development Recombinant human single-chain urokinase-type plasminogen activator mutant produced by site-specific mutagenesis of lysine 158 to histidine 158
AU3410289A (en) 1988-04-22 1989-11-24 Collaborative Research Inc. Plasminogen activators with increased fibrin selectivity
GB8822147D0 (en) 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
WO1990004635A1 (en) 1988-10-27 1990-05-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Thrombolytic agents with modified kringle domains
CA2047702C (en) * 1989-03-06 2000-10-24 Joseph F. Sambrook Serpin resistant chymotrypsin superfamily proteases particularly pai-1 resistant t-pa, complementary inhibitor mutants; compositions; genes; expression
EP0387380A1 (en) * 1989-03-17 1990-09-19 BEHRINGWERKE Aktiengesellschaft Mutants of urinary plasminogen activator, their production and use
EP0467932B1 (en) 1989-04-07 2000-10-18 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor
US5891664A (en) 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5129569A (en) 1989-12-21 1992-07-14 Stanton Norman C Apparatus to attach a flexible covering to a semi-rigid member
US5648253A (en) 1990-12-20 1997-07-15 Tsi Corporation Inhibitor-resistant urokinase
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
GB9216558D0 (en) 1992-08-04 1992-09-16 British Bio Technology Modified proteases
US5571708A (en) 1993-04-19 1996-11-05 Bristol-Myers Squibb Company Thrombin-activatable plasminogen activator
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5472692A (en) * 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
DK0690127T3 (da) 1994-03-31 1999-05-03 Amgen Inc Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
ATE226642T1 (de) 1994-07-07 2002-11-15 Tno Modifizierte proenzyme als substrate für proteolische enzyme
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996013160A1 (en) 1994-11-01 1996-05-09 New England Deaconess Hospital Use of urokinase-type plasminogen activators to inhibit hiv infectivity
US5980886A (en) 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US7070925B1 (en) 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US20020106775A1 (en) 1999-03-05 2002-08-08 Jieyi Wang Highly crystalline urokinase
WO1999045964A1 (en) 1998-03-12 1999-09-16 Shearwater Polymers, Incorporated Poly(ethylene glycol) derivatives with proximal reactive groups
CA2336399A1 (en) 1998-07-03 2000-01-13 Neles Field Controls Oy Method and arrangement for measuring fluid
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1157275A4 (en) 1999-02-28 2003-01-15 Univ Washington NEW TRANSDUCTION MOLECULES AND METHOD FOR USING THE SAME
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
JP4861586B2 (ja) 1999-12-22 2012-01-25 ネクター セラピューティックス 水溶性ポリマーの立体的に妨害される誘導体
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
JP4873818B2 (ja) 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2001094332A1 (en) 2000-06-02 2001-12-13 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002228636A1 (en) 2000-11-17 2002-05-27 Genaissance Pharmaceuticals, Inc. Haplotypes of the plau gene
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
WO2002049673A2 (en) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7192468B2 (en) 2002-04-15 2007-03-20 Fluor Technologies Corporation Configurations and method for improved gas removal
SG166001A1 (en) 2002-10-02 2010-11-29 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060178297A1 (en) 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
ES2911435T3 (es) 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CN1311076C (zh) 2003-04-16 2007-04-18 普罗特奥姆技术公司 生产重组尿激酶的方法
CA2426115A1 (en) 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
BRPI0417107A (pt) 2003-12-19 2007-02-06 Genentech Inc fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
GB0405330D0 (en) 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
JP5014149B2 (ja) 2004-12-23 2012-08-29 ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー マンナン結合性レクチンを伴うセリンプロテアーゼ（ｍａｓｐ）及びその複合体の機能的決定方法
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
AU2006308989A1 (en) 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Novel protein transduction domains and uses therefor
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
US20090010916A1 (en) 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
EP2242501A4 (en) 2008-01-09 2011-10-19 Intrexon Corp THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE

Also Published As

Publication number Publication date
AU2019413431A1 (en) 2021-07-08
PE20211664A1 (es) 2021-08-26
CL2021001710A1 (es) 2021-12-17
CA3123872A1 (en) 2020-07-02
CO2021008338A2 (es) 2021-10-29
KR20210110848A (ko) 2021-09-09
IL284323A (en) 2021-08-31
CA3176021A1 (en) 2020-07-02
JP2022516725A (ja) 2022-03-02
US20230242895A1 (en) 2023-08-03
JOP20210146A1 (ar) 2023-01-30
EP3902913A1 (en) 2021-11-03
BR112021012601A2 (pt) 2021-11-30
CN113661239A (zh) 2021-11-16
WO2020140101A1 (en) 2020-07-02
SG11202106244RA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PH12019502838A1 (en) Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
PH12018501955A1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
MY201450A (en) Substituted inhibitors of menin-mll and methods of use
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
JOP20210146A1 (ar) بولي ببتيدات منشط بلازمينوجين من نوع يوروكيناز معدلة وطرق استخدامها
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
Niego et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin
EA202191852A1 (ru) Необратимые ингибиторы взаимодействия менин-mll
MX2021010809A (es) Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma.
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
AU2016255474A8 (en) Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease
EA202091325A1 (ru) Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток
WO2018138032A3 (en) NKp46 BINDING AGENTS
WO2019027299A3 (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
EA202000017A1 (ru) Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения
TH1701001481A (th) เอนไซม์ที่ถูกละลายและการใช้มัน
Deduhina STATE AND ECONOMY IN THE SPHERE OF ENTREPRENEURIAL ACTIVITY LEGAL REGULATION
EA201892083A1 (ru) Замещенные ингибиторы менина-mll и способы применения
UA106449U (uk) Спосіб корекції експериментальної діабетичної ретинопатії